194 related articles for article (PubMed ID: 16598051)
1. Letrozole or tamoxifen in early breast cancer.
Buzdar AU; Baum M; Cuzick J
N Engl J Med; 2006 Apr; 354(14):1528-30; author reply 1528-30. PubMed ID: 16598051
[No Abstract] [Full Text] [Related]
2. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
3. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
4. [Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
Bruntsch U
MMW Fortschr Med; 2002 Sep; 144(38):20. PubMed ID: 12395697
[No Abstract] [Full Text] [Related]
5. Letrozole or tamoxifen in early breast cancer.
Chlebowski RT
N Engl J Med; 2006 Apr; 354(14):1528-30; author reply 1528-30. PubMed ID: 16602149
[No Abstract] [Full Text] [Related]
6. Extended adjuvant therapy for breast cancer--how much is enough?
Prowell TM; Stearns V
J Natl Cancer Inst; 2007 Dec; 99(24):1825-7. PubMed ID: 18073372
[No Abstract] [Full Text] [Related]
7. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
8. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
9. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
10. Bone safety of aromatase inhibitors versus tamoxifen.
Lønning PE
Int J Gynecol Cancer; 2006; 16 Suppl 2():518-20. PubMed ID: 17010062
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid prevents cancer treatment-induced bone loss.
Oncology (Williston Park); 2005 Mar; 19(3):390. PubMed ID: 15828553
[No Abstract] [Full Text] [Related]
12. ATAC trial update.
de Castro G
Lancet; 2005 Apr 2-8; 365(9466):1225; author reply 1225-6. PubMed ID: 15811448
[No Abstract] [Full Text] [Related]
13. Letrozole or tamoxifen in early breast cancer.
Erban JK
N Engl J Med; 2006 Apr; 354(14):1528-30; author reply 1528-30. PubMed ID: 16602148
[No Abstract] [Full Text] [Related]
14. Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
Nabholtz JM; Reese DM
Breast Cancer; 2001; 8(4):305-9. PubMed ID: 11791122
[No Abstract] [Full Text] [Related]
15. Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial.
Sestak I; Sapunar F; Cuzick J
J Clin Oncol; 2009 Oct; 27(30):4961-5. PubMed ID: 19752338
[TBL] [Abstract][Full Text] [Related]
16. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
17. [Consensus Meeting of the 9th International Conference on Primary Therapy of Early Breast Cancer (St. Gall, January 26-29, 2005)].
Thürlimann B; Senn HJ
Gynakol Geburtshilfliche Rundsch; 2005 Jun; 45(3):143-6. PubMed ID: 15990439
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen vs the aromatase inhibitors: news from San Antonio, 2001.
Munster PN; Horton J
Cancer Control; 2001; 8(6):478-9. PubMed ID: 11807416
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
20. Anastrozole for breast cancer: recent advances and ongoing challenges.
Buzdar AU
Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
